Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

IPSEN Aktie

 >IPSEN Aktienkurs 
116.9 EUR    -0.4%    (Tradegate)
Ask: 116.5 EUR / 9 Stück
Bid: 115.9 EUR / 9 Stück
Tagesumsatz: 10 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IPSEN Aktie über LYNX handeln
>IPSEN Performance
1 Woche: +0,3%
1 Monat: +4,4%
3 Monate: +14,4%
6 Monate: +5,2%
1 Jahr: +7,8%
laufendes Jahr: +5,9%
>IPSEN Aktie
Name:  IPSEN S.A. PORT. EO 1
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0010259150 / A0ESMG
Symbol/ Ticker:  I7G (Frankfurt)
Kürzel:  FRA:I7G, ETR:I7G, I7G:GR
Index:  -
Webseite:  https://www.ipsen.com/
Profil:  Ipsen S.A. is a global biopharmaceutical company s..
>Volltext..
Marktkapitalisierung:  9588.7 Mio. EUR
Unternehmenswert:  9107.16 Mio. EUR
Umsatz:  3589.94 Mio. EUR
EBITDA:  1606.91 Mio. EUR
Nettogewinn:  451.53 Mio. EUR
Gewinn je Aktie:  5.46 EUR
Schulden:  969.59 Mio. EUR
Liquide Mittel:  1456.7 Mio. EUR
Operativer Cashflow:  980.88 Mio. EUR
Bargeldquote:  1.02
Umsatzwachstum:  9.57%
Gewinnwachstum:  -34.25%
Dividende je Aktie:  1.4 EUR
Dividendenrendite:  1.21%
Dividendenschätzung:  1.21%
Div. Historie:  04.06.25 - 1.4€
30.05.24 - 1.2€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  IPSEN
Letzte Datenerhebung:  30.08.25
>IPSEN Kennzahlen
Aktien/ Unternehmen:
Aktien: 82.71 Mio. St.
Frei handelbar: 41.78%
Leerverk. Aktien: -
Rückkaufquote: 0.35%
Mitarbeiter: 5358
Umsatz/Mitarb.: 0.56 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 9.66%
Bewertung:
KGV: 21.67
KGV lG: 11.05
KUV: 2.76
KBV: 2.27
PEG-Ratio: -
EV/EBITDA: 5.67
Rentabilität:
Bruttomarge: 82.39%
Gewinnmarge: 12.58%
Operative Marge: 33.67%
Managementeffizenz:
Gesamtkaprendite: 6.7%
Eigenkaprendite: 10.82%
>IPSEN Peer Group

Es sind 70 Aktien bekannt.
 
29.08.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025 (GlobeNewswire EN)
 
Aggregated presentation by day and by market Statement of transactions in own shares from August 18th to August 22nd 2025...
27.08.25 - 18:03
Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
05.08.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
31.07.25 - 19:27
Ipsen S.A. reports 1H results, FY25 guidance (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.07.25 - 18:03
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) (GlobeNewswire EN)
 
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)...
31.07.25 - 13:27
Ipsen shares fall 6% as guidance raise overshadowed by product misses (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
31.07.25 - 10:30
Ipsen H1 Profit Rises On Sales Growth; Raises Annual Sales Outlook (AFX)
 
PARIS (dpa-AFX) - Ipsen SA (IPSEY) Thursday reported net profit of 334 million euros or 4 euros per share for the first half, up from 232 million euros or 2.78 euros per share in the comparable pe......
24.07.25 - 20:15
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.07.25 - 19:45
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors (GlobeNewswire EN)
 
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues....
23.07.25 - 07:33
Ipsen announces changes to its Executive Committee (GlobeNewswire EN)
 
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...
22.07.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
16.07.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
10.07.25 - 18:33
Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
08.07.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2025 (GlobeNewswire EN)
 
Aggregated presentation by day and by market...
08.07.25 - 16:01
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors (PR Newswire)
 
Milestone marks a key advancement in the partnership with Ipsen. MONTRÉAL , July 8, 2025 /PRNewswire/ - IRIC and IRICoR today announced the start of a Phase 1 clinical trial of its small molecule therapy for solid tumors licensed to Ipsen. This marks a major milestone in the strategic......
07.07.25 - 18:03
Ipsen - Half year statement - 2025 06 30 (GlobeNewswire EN)
 
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
01.07.25 - 18:03
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025 (GlobeNewswire EN)
 
 Aggregated presentation by day and by market...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Humorist lustwandelt innerhalb der Unendlichkeit. - Arthur Schnitzler
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!